HCP
NVO

Hardin Capital Partners’s Novo Nordisk NVO Stock Holding History

Hardin Capital Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$314K Buy
6,520
+116
+2% +$4.98K 0.15% 98
2026
Q1 		$235K Buy
+6,404
New +$303K 0.11% 123

Other funds holding NVO

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
MG
Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Hardin Capital Partners's NVO Position: Q2 2026 in Review

Hardin Capital Partners increased its Novo Nordisk (NVO) stake by 1.8% in Q2 2026, buying an estimated $4.98K and bringing the position to 6,520 shares worth $314K. The position accounts for 0.15% of the portfolio, ranked #98.

Hardin Capital Partners first reported a position in NVO in Q1 2026 and has held it in 2 quarters since. 756 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Hardin Capital Partners held 6,520 shares of Novo Nordisk worth $314K as of Q2 2026.
  • Hardin Capital Partners bought 116 Novo Nordisk shares in Q2 2026, an estimated $4.98K.
  • Novo Nordisk made up 0.15% of Hardin Capital Partners's portfolio in Q2 2026, its #98 holding.
  • Hardin Capital Partners first reported a position in Novo Nordisk in Q1 2026 and has held it in 2 quarters since.
  • 756 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Hardin Capital Partners's 13F filing for Q2 2026, filed 7 Jul 2026.